July 10, 2017
McKesson Packaging Services is recalling bupropion HCL tablets, USP, 75 mg, packaged as UD 100 tablets (10x10) and manufactured by Sandoz Inc. The voluntary recall was initiated after testing revealed the product did not meet specifications for moisture content, according to the July 5, 2017, US Food and Drug Administration (FDA) Enforcement Report.
Drug Recalled Due to Labelling Error
Nocebo Effect Increases Generic Drug Complaints
The recall spans 942 cartons distributed throughout the United States from 5 lots:
- 0113148, 0113149, and 0113150 (Exp. 4/18);
- 0113636 (Exp. 6/18); and
- 0114513 (Exp. 10/18).
McKesson Packaging Services initiated the recall May 30, 2017. On June 29, 2017, the FDA categorized the recall class III, indicating use of the product is not likely to cause any adverse health consequences.
Bupropion is a prescription antidepressant used to treat depression, seasonal affective disorder, and other mental health issues.